PAM
KRYS icon

Panagora Asset Management’s Krystal Biotech KRYS Stock Holding History

Panagora Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,788
Closed -$31K – 2492
2018
Q3 		$31K Buy
+1,788
New +$30K ﹤0.01% 2136

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Panagora Asset Management's KRYS Position: Q4 2018 in Review

Panagora Asset Management sold out of Krystal Biotech (KRYS) in Q4 2018, closing a stake of 1,788 shares — an estimated $31K sold.

Panagora Asset Management first reported a position in KRYS in Q3 2018 and held it in 1 quarter. The position peaked at $31K in Q3 2018. 45 funds tracked by Wall St. Rank hold KRYS as of Q4 2018.

  • Panagora Asset Management reported no remaining Krystal Biotech position as of Q4 2018 after selling out during the quarter.
  • Panagora Asset Management sold 1,788 Krystal Biotech shares in Q4 2018, an estimated $31K.
  • Panagora Asset Management first reported a position in Krystal Biotech in Q3 2018 and held it in 1 quarter.
  • Panagora Asset Management's Krystal Biotech position peaked at $31K in Q3 2018.
  • 45 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2018.

Based on Panagora Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.